Literature DB >> 501206

Tyrosine metabolism in cirrhosis.

B M Nordlinger, J T Fulenwider, G L Ivey, B A Faraj, F M Ali, M Kutner, J M Henderson, D Rudman.   

Abstract

The aim of this study was to define the enzyme defect responsible for tyrosinemia in cirrhotic patients. The principal hepatic degradation pathway for tyrosine, tyrosine leads to p-hydroxyphenylpyruvic acid equilibrium homogentisic acid leads to CO2 was studied in 18 cirrhotic patients and eight controls. The classic method employed in elucidation of hereditary tyrosinosis was sued. Metabolic intermediates on the pathway were measured in the basal state, and following oral loading doses (50 mg/kg BW) of tyrosine, PHPA, and homogentisic acid. Cirrhotic patients showed a significant increase (p = 0.005) in fasting plasma tyrosine and in basal PHPA excretion and impaired tolerance to all three metabolites when compared to normals. Fifteen of the 18 cirrhotic patients showed tyrosine intolerance which was not accompanied by change in distal metabolites compared to their basal levels. Nevertheless 13 of the 18 did exhibit intolerance of either PHPA or homogentisic acid. We conclude that in contrast to the single complete defect in hereditary disorders of tyrosine metabolism, cirrhotic patients have partial defects at tyrosine transaminase, PHPA oxidase, and homogentisic acid oxidase, the initial step being rate-limiting.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 501206

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  5 in total

1.  Coagulation defect of congenital tyrosinaemia.

Authors:  S Ozsoylu
Journal:  Arch Dis Child       Date:  1985-02       Impact factor: 3.791

2.  Tyrosine transaminase activity in normal and cirrhotic liver.

Authors:  J M Henderson; B A Faraj; F M Ali; D Rudman
Journal:  Dig Dis Sci       Date:  1981-02       Impact factor: 3.199

3.  Total parenteral nutrition with F080 in cirrhotics with subclinical encephalopathy.

Authors:  W J Millikan; J M Henderson; W D Warren; S P Riepe; M H Kutner; L Wright-Bacon; C Epstein; R B Parks
Journal:  Ann Surg       Date:  1983-03       Impact factor: 12.969

4.  Characteristics change in serum amino acid levels in different types of hepatic encephalopathy.

Authors:  A Watanabe; S Hayashi; T Higashi; T Obata; T Sakata; N Takei; T Shiota; H Nagashima
Journal:  Gastroenterol Jpn       Date:  1982

5.  Comparison of the effects of Hepatic-Aid and a Casein modular diet on encephalopathy, plasma amino acids, and nitrogen balance in cirrhotic patients.

Authors:  A McGhee; J M Henderson; W J Millikan; J C Bleier; R Vogel; M Kassouny; D Rudman
Journal:  Ann Surg       Date:  1983-03       Impact factor: 12.969

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.